Know what drives value.
Be ahead when it matters.
For founders, executives, boards and investors who need to see what will drive decisions tomorrow — and act while options remain open.
Deal making
Value perception
Optionality
Governance
For those in innovative Life Sciences and High Growth / High Risk who prepare, make, stress-test and question key decisions — in a world of at-risk science, asymmetric outcomes event-driven value and targeted choices.
Why we are made for this Our take on Life Sciences
Our view on value:
In innovative Life Sciences, value does not emerge linearly. It results from a series of decisions that influence how future opportunities, risks and strategic choices unfold. It thus results from readiness, and from the signals — intentionally built, or mistakenly sent.
The most important decisions are often made long before their consequences become visible. Financing structures, alignment, incentives and governance arrangements, partnering strategies and development priorities create a framework that can either expand or constrain future possibilities.
The best companies do not wait until a financing, partnership or transaction is on the horizon to think about leverage and optionality. They build the conditions that preserve them years in advance.
That is why we focus on the strategic foundations of value: understanding how different stakeholders make decisions, what signals they respond to, and how today's choices influence tomorrow's room to maneuver.
We believe value truly emerges when:
- a team can execute
- capital structure allows action
- governance enables the right decision at the right time
Ideas inspire.
Decisions create value.
Readiness anchors value
R&D doesn´t sell by itself.
Value materializes when a company is ready to operate in the real.
We assess how close a company truly is to market reality, investor expectations and deal making— beyond scientific progress alone.
Value is signal-sensitive
In High Growth / High Risk markets, signals amplify outcomes.
We capture how market participants decide — individually and collectively:
- which signals they recognize,
- which they discount,
- which they are compelled to price.
✽ Who this page is for
For those who carry the full picture
Read the full game
Building in life sciences or deep tech. Facing a financing event, a partnering decision, or a governance inflection. You need someone who reads the full game — science to term sheet — without needing to be brought up to speed.
Responsible for decisions
Responsible for decisions where the margin for error is asymmetric. You need a perspective that crosses silos — not just the financial model, not just the strategy, but their intersection at this specific stage and structure.
Generate alpha & beta
Holding High Growth / High Risk assets. Playing a long game and short moves in a field where the signal that matters is subtle and early. You need longitudinal exposure to what elevates and erodes value across market, stages and deal structures.
✽ What the work actually is
Four dimensions into one coherent picture
FINANCING INTELLIGENCE
How the next round should be structured to maximise future optionality — not just this raise.
Analysing the downstream consequences of current term choices, the signals the cap table sends to the next investor type, and the narrative consistency between the equity story and the asset reality.
Decisions made here are felt at the next round, at partnering, at exit.
VALUE ARCHITECTURE
What makes value in this asset, at this stage, for this investor type — and what is currently limiting it.
Mapping the asset reality, the capital structure constraints, the governance dynamics, and the ecosystem signals that determine what is visible to the market and what is not.
This is the analytical base from which every subsequent decision should be made.
PARTNERING & DEAL PREP AND EXECUTION
What the pharma partner, strategic acquirer, or co-investor will actually read — and what they will not say out loud.
The executive is the deal. Surprise is where emotion takes over. Preparation is where it does not get the chance.
In the background: asset positioning, deal structure scenarios, term analysis, counterpart logic — so the executive arrives at every conversation with the full picture, and holds it visibly.
GOVERNANCE & THE LONG GAME
The decisions that appear minor today and become structural three years from now.
Alignment, incentives and governance arrangements, milestone design — each one is a signal to future investors and a constraint on future decisions.
Readiness means identifying the fractures before they become visible. That is when they are still cheap to address.
✽ Context is where value lives
Every company is a different playboard.
Two companies can face the same financing decision, the same governance tension, the same partnering question — and require completely different responses, because the asset reality, the capital structure, the stakeholder dynamics and the competitive window are never the same twice.
Therefore we start with value reality.
Our work is built around 1 question: where is the true value and what limits it?
Value is not only embedded in the asset or product itself — it lives in the human and organisational dynamics around it. What a company, its board, cap table, and partners are able to make of it. That is why our reading begins at the first conversation — and never really stops. Three dimensions, held simultaneously:
Asset reality
What the science actually supports, where the value is genuinely defensible, and where the gaps are that others will find before you do.
Financial & structural readiness
What the current capital structure signals to the next investor type, what the governance arrangements constrain, and what the incentive design rewards or undermines.
Ecosystem & execution context
Who the relevant counterparts are, what they are optimising for, and what the competitive and regulatory signals are saying that the company may not yet be reading.
This scan is the playboard. It is what makes the work specific rather than templated.
Our continuous exposure across stages, outcomes and market cycles gives us a longitudinal view of what elevates — and erodes — value, and how this differs across FO-, VC-backed and listed companies, depending on founder involvement, top management composition, incentives and governance practice. This enables founders, management teams, boards and investors to align capital, governance and strategy with science and turn complexity into greater, durable value.
Deal outcomes are often determined before the process even begins.
Because readiness — of assets, teams and counterparts — sets the play.
To improve outcomes, you must read the game early. Understand how others see it and decide before options quietly expire.